FluCyD combination in low-grade lymphomas: An active regimen for selected patients

Licia Siracusano, Monica Balzarotti, Massimo Magagnoli, Luca Castagna, Cristina Ripa, Andrea Nozza, Walter Torri, Barbara Sarina, Luciano Isa, Alexia Bertuzzi, Inna Timofeeva, Emanuela Morenghi, Armando Santoro

Research output: Contribution to journalArticle

Abstract

A phase-two trial evaluating the synergistic activity and toxicity of fludarabine, cyclophosphamide and dexamethasone (FluCyD) in untreated and pre-treated low-grade lymphoproliferative disorders is presented. Patients were given fludarabine 20 mg/m2 on days 1-5, cyclophosphamide 1000 mg/m2 on day 1, dexamethasone 20 mg on days 1-5, every four weeks for a maximum of six courses in untreated cases, and for four courses in pre-treated cases allocated to high-dose consolidation. One patient refused high dose program for persistent disease, and was treated with rituximab. A total of 29 patients were included. The overall response rate was 89%, with actuarial three-year disease free survival and overall survival 56% and 72%, respectively. Haematological toxicity was limited, and main complications of therapy were infections: one patient died of Jacob-Creutzfeld virus encephalitis after FluCyD and rituximab and three other cases, with concomitant or subsequent autoimmune disease requiring immunosuppression, developed central nervous system infection. Nine patients were scheduled to mobilize progenitor cells with chemotherapy and G-CSF. Only two patients mobilized an adequate amount of CD34+, while in two further cases bone marrow harvest was performed, but the product was considered inadequate in one. One patient died after mobilization chemotherapy, because of haemolytic anaemia complicated with acute renal failure. Despite its effectiveness in indolent lymphoproliferative disorders, the incidence of infections, as well as the impact of fludarabine on subsequent peripheral blood stem cell mobilization, suggest that more careful selection criteria must applied before patients are allocated to this regimen.

Original languageEnglish
Pages (from-to)357-362
Number of pages6
JournalHAEMA
Volume7
Issue number3
Publication statusPublished - Jul 2004

Fingerprint

Non-Hodgkin's Lymphoma
Cyclophosphamide
Dexamethasone
Lymphoproliferative Disorders
Encephalitis Viruses
Hematopoietic Stem Cell Mobilization
Drug Therapy
Central Nervous System Infections
fludarabine
Hemolytic Anemia
Granulocyte Colony-Stimulating Factor
Infection
Acute Kidney Injury
Immunosuppression
Patient Selection
Autoimmune Diseases
Disease-Free Survival
Stem Cells
Bone Marrow
Survival

Keywords

  • Chemotherapy
  • Fludarabine
  • Low grade lymphomas
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

FluCyD combination in low-grade lymphomas : An active regimen for selected patients. / Siracusano, Licia; Balzarotti, Monica; Magagnoli, Massimo; Castagna, Luca; Ripa, Cristina; Nozza, Andrea; Torri, Walter; Sarina, Barbara; Isa, Luciano; Bertuzzi, Alexia; Timofeeva, Inna; Morenghi, Emanuela; Santoro, Armando.

In: HAEMA, Vol. 7, No. 3, 07.2004, p. 357-362.

Research output: Contribution to journalArticle

Siracusano, L, Balzarotti, M, Magagnoli, M, Castagna, L, Ripa, C, Nozza, A, Torri, W, Sarina, B, Isa, L, Bertuzzi, A, Timofeeva, I, Morenghi, E & Santoro, A 2004, 'FluCyD combination in low-grade lymphomas: An active regimen for selected patients', HAEMA, vol. 7, no. 3, pp. 357-362.
Siracusano, Licia ; Balzarotti, Monica ; Magagnoli, Massimo ; Castagna, Luca ; Ripa, Cristina ; Nozza, Andrea ; Torri, Walter ; Sarina, Barbara ; Isa, Luciano ; Bertuzzi, Alexia ; Timofeeva, Inna ; Morenghi, Emanuela ; Santoro, Armando. / FluCyD combination in low-grade lymphomas : An active regimen for selected patients. In: HAEMA. 2004 ; Vol. 7, No. 3. pp. 357-362.
@article{74024ccd208342cb9267cf615ee297a0,
title = "FluCyD combination in low-grade lymphomas: An active regimen for selected patients",
abstract = "A phase-two trial evaluating the synergistic activity and toxicity of fludarabine, cyclophosphamide and dexamethasone (FluCyD) in untreated and pre-treated low-grade lymphoproliferative disorders is presented. Patients were given fludarabine 20 mg/m2 on days 1-5, cyclophosphamide 1000 mg/m2 on day 1, dexamethasone 20 mg on days 1-5, every four weeks for a maximum of six courses in untreated cases, and for four courses in pre-treated cases allocated to high-dose consolidation. One patient refused high dose program for persistent disease, and was treated with rituximab. A total of 29 patients were included. The overall response rate was 89{\%}, with actuarial three-year disease free survival and overall survival 56{\%} and 72{\%}, respectively. Haematological toxicity was limited, and main complications of therapy were infections: one patient died of Jacob-Creutzfeld virus encephalitis after FluCyD and rituximab and three other cases, with concomitant or subsequent autoimmune disease requiring immunosuppression, developed central nervous system infection. Nine patients were scheduled to mobilize progenitor cells with chemotherapy and G-CSF. Only two patients mobilized an adequate amount of CD34+, while in two further cases bone marrow harvest was performed, but the product was considered inadequate in one. One patient died after mobilization chemotherapy, because of haemolytic anaemia complicated with acute renal failure. Despite its effectiveness in indolent lymphoproliferative disorders, the incidence of infections, as well as the impact of fludarabine on subsequent peripheral blood stem cell mobilization, suggest that more careful selection criteria must applied before patients are allocated to this regimen.",
keywords = "Chemotherapy, Fludarabine, Low grade lymphomas, Stem cell transplantation",
author = "Licia Siracusano and Monica Balzarotti and Massimo Magagnoli and Luca Castagna and Cristina Ripa and Andrea Nozza and Walter Torri and Barbara Sarina and Luciano Isa and Alexia Bertuzzi and Inna Timofeeva and Emanuela Morenghi and Armando Santoro",
year = "2004",
month = "7",
language = "English",
volume = "7",
pages = "357--362",
journal = "HAEMA",
issn = "1108-2682",
publisher = "Haema Journal",
number = "3",

}

TY - JOUR

T1 - FluCyD combination in low-grade lymphomas

T2 - An active regimen for selected patients

AU - Siracusano, Licia

AU - Balzarotti, Monica

AU - Magagnoli, Massimo

AU - Castagna, Luca

AU - Ripa, Cristina

AU - Nozza, Andrea

AU - Torri, Walter

AU - Sarina, Barbara

AU - Isa, Luciano

AU - Bertuzzi, Alexia

AU - Timofeeva, Inna

AU - Morenghi, Emanuela

AU - Santoro, Armando

PY - 2004/7

Y1 - 2004/7

N2 - A phase-two trial evaluating the synergistic activity and toxicity of fludarabine, cyclophosphamide and dexamethasone (FluCyD) in untreated and pre-treated low-grade lymphoproliferative disorders is presented. Patients were given fludarabine 20 mg/m2 on days 1-5, cyclophosphamide 1000 mg/m2 on day 1, dexamethasone 20 mg on days 1-5, every four weeks for a maximum of six courses in untreated cases, and for four courses in pre-treated cases allocated to high-dose consolidation. One patient refused high dose program for persistent disease, and was treated with rituximab. A total of 29 patients were included. The overall response rate was 89%, with actuarial three-year disease free survival and overall survival 56% and 72%, respectively. Haematological toxicity was limited, and main complications of therapy were infections: one patient died of Jacob-Creutzfeld virus encephalitis after FluCyD and rituximab and three other cases, with concomitant or subsequent autoimmune disease requiring immunosuppression, developed central nervous system infection. Nine patients were scheduled to mobilize progenitor cells with chemotherapy and G-CSF. Only two patients mobilized an adequate amount of CD34+, while in two further cases bone marrow harvest was performed, but the product was considered inadequate in one. One patient died after mobilization chemotherapy, because of haemolytic anaemia complicated with acute renal failure. Despite its effectiveness in indolent lymphoproliferative disorders, the incidence of infections, as well as the impact of fludarabine on subsequent peripheral blood stem cell mobilization, suggest that more careful selection criteria must applied before patients are allocated to this regimen.

AB - A phase-two trial evaluating the synergistic activity and toxicity of fludarabine, cyclophosphamide and dexamethasone (FluCyD) in untreated and pre-treated low-grade lymphoproliferative disorders is presented. Patients were given fludarabine 20 mg/m2 on days 1-5, cyclophosphamide 1000 mg/m2 on day 1, dexamethasone 20 mg on days 1-5, every four weeks for a maximum of six courses in untreated cases, and for four courses in pre-treated cases allocated to high-dose consolidation. One patient refused high dose program for persistent disease, and was treated with rituximab. A total of 29 patients were included. The overall response rate was 89%, with actuarial three-year disease free survival and overall survival 56% and 72%, respectively. Haematological toxicity was limited, and main complications of therapy were infections: one patient died of Jacob-Creutzfeld virus encephalitis after FluCyD and rituximab and three other cases, with concomitant or subsequent autoimmune disease requiring immunosuppression, developed central nervous system infection. Nine patients were scheduled to mobilize progenitor cells with chemotherapy and G-CSF. Only two patients mobilized an adequate amount of CD34+, while in two further cases bone marrow harvest was performed, but the product was considered inadequate in one. One patient died after mobilization chemotherapy, because of haemolytic anaemia complicated with acute renal failure. Despite its effectiveness in indolent lymphoproliferative disorders, the incidence of infections, as well as the impact of fludarabine on subsequent peripheral blood stem cell mobilization, suggest that more careful selection criteria must applied before patients are allocated to this regimen.

KW - Chemotherapy

KW - Fludarabine

KW - Low grade lymphomas

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=4043171185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043171185&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:4043171185

VL - 7

SP - 357

EP - 362

JO - HAEMA

JF - HAEMA

SN - 1108-2682

IS - 3

ER -